Dual targeting of the epigenome via FACT complex and histone deacetylase is a potent treatment strategy for DIPG

May 13, 2021
In 2019 Dr. Maria Tsoli and Dr. David Ziegler of Children’s Cancer Institute proposed developing new epigenetic combination treatments against DIPG. This project was approved for funding by the DIPG/DMG Collaborative and here are the results: Abstract Diffuse intrinsic pontine glioma (DIPG) is an aggressive and incurable childhood brain tumor for which new treatments are needed. CBL0137 is an anti-cancer compound developed from quinacrine that targets facilitates chromatin transcription (FACT)…

Australian Researchers Find New Way to Target Deadly Childhood Cancer With CBL0137

April 13, 2021
The following work was supported by grants from the DIPG/DMG Collaborative. Research by Australian scientists could pave the way to a new treatment for a currently incurable brain cancer in children called Diffuse Intrinsic Pontine Glioma, or DIPG. Affecting about 150-300 children in US each year, DIPG is a devastating disease with a median survival range of 8-11 months, according to The research, led by scientists at Children’s Cancer Institute and published this week in the interna…

Research Update: A Pilot Radiogenomic Study of DIPG Reveals Distinct Subgroups With Unique Clinical Trajectories and Therapeutic Targets

January 14, 2021
This project was approved for funding by the DIPG/DMG Collaborative and here are the results: Quote from Dr. Rachid Drissi: “This is the first study to apply an approach combining magnetic resonance imaging (MRI) features and genomics in patients with DIPG in order to (1) investigate relationships between MRI characteristics at post-radiotherapy time points with tumor molecular profiles identified through extensive genome-wide sequencing analyses, and (2) further explore the radiographic, clin…